Sirolimus
Originally developed as a transplant anti-rejection drug, this medication suppresses the immune system and blocks a cellular growth pathway called mTOR. It is also used to treat certain rare kidney diseases, some hormone-sensitive cancers, and non-cancerous tumors that arise in genetic conditions such as tuberous sclerosis.
分子量
914.2000 g/mol
LogP
6.00
TPSA
195.00 Ų
リピンスキーの五則
不適合
治療領域
Pharmacokinetics (PK)
Pharmacodynamics (PD)
2D構造
Cite this structure
Embed this structure
SMILES
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
InChI
InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
Molecular Formula
C51H79NO13
HBD / HBA
3 / 13
回転可能結合数
6
重原子数
65
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
Originally developed as a transplant anti-rejection drug, this medication suppresses the immune system and blocks a cellular growth pathway called mTOR. It is also used to treat certain rare kidney diseases, some hormone-sensitive cancers, and non-cancerous tumors that arise in genetic conditions such as tuberous sclerosis.
Yes, Sirolimus is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL413. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5284616. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sirolimus"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sirolimus/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sirolimus/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sirolimus/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sirolimus"></drugfyi-drug>